Search
Biocentury Emerging Company Profile - Accession: precisely targeted oncolytic viruses
- davidtokley
- Nov 29, 2022
- 1 min read
Updated: Jan 3, 2023
Bent Jakobsen’s newest biotech is replacing the virus’ natural tropisms with an integrin-based cancer targeting mechanism - read the article by Richard Guy, Biopharma Analyst, here >

Comments